Last updated: 2026-11-15 15:16:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Spero Therapeutics, Inc. (SPRO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.00, with a market capitalization of $58.26M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.95 to $3.08. This page covers its latest market performance, valuation, price trends and company information.
$58.26M | |
$1.04 | |
$1.04 | |
$0.96 | |
$1.00 | |
351.07K | |
534.73K | |
-- | |
$3.08 | |
$0.95 | |
-- | |
-- |
Spero Therapeutics, Inc. (SPRO) last closed at $1.00 as of 2026-11-14 01:00:00, down 0.80% ($0.01) from the previous close of $1.00.
During the latest regular trading session, SPRO traded between $0.96 and $1.04, with a volume of 351.07K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Spero Therapeutics, Inc. (SPRO) moved from $1.02 to $1.00, representing a decline of 1.96% ($0.02).
The stock traded between $0.95 and $1.08 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 331.75 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.3%
SPRO is currently trading at $1.00, placing it 2.3% of the way from its 52-week low of $0.95 to its 52-week high of $3.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 25 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Spero Therapeutics, Inc. and SPRO stock.
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.47) by 65.96 percent. This is a 23.08 percent decrease over losses of $(0.13) per share
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.47) by 61.7 percent. This is a 484.62 percent decrease over losses of $(0.13) per share
Eligible investors can buy real shares of Spero Therapeutics, Inc. (SPRO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to SPRO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between SPRO shares and USD.
SPRO Shares to USD
1.00 SPRO shares = 1 USD
Calculations are estimates based on the latest available price and are for reference only.
